Patents by Inventor Michael John PARNHAM
Michael John PARNHAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944613Abstract: The present invention pertains to novel treatments of neuropathic pain; in particular chemotherapy induced peripheral neuropathic pain (CIPNP). The invention provides antagonists cytochrome P450 epoxygenases (CYP), and more specifically antagonists of CYP2J2, as therapeutics for use in the treatment of neuropathic pain such as CIPNP. CYP2J2 antagonists were identified to alleviate CIPNP in-vivo, and therefore are provided additionally in combination with chemotherapeutics for the treatment of diseases such as cancer or other proliferative disorders. The CYP2J2 antagonists reduce chemotherapeutic induced pain and therefore allow for a higher dosing of the chemotherapeutic during cancer treatment. In addition the invention relates to the use of CYP2J2 agonists, or metabolites of CYP2J2, for sensitizing TRPV1.Type: GrantFiled: October 7, 2019Date of Patent: April 2, 2024Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.Inventors: Marco Sisignano, Christian Brenneis, Klaus Scholich, Gerd Geisslinger, Sebastian Zinn, Michael John Parnham
-
Publication number: 20230174619Abstract: The present invention relates to a PD-L1 polypeptide comprising at least a first amino acid sequence at least 70% identical to SEQ ID NO:8, and at least a second sequence at least 70% identical to SEQ ID NO: 10, wherein the polypeptide carries amino acid substitutions at least at the amino acid positions Y56 and P76, wherein the amino acid positions are based on the murine PD-L1 amino acid sequence (SEQ ID NO:6). The present invention also relates to a polynucleotide encoding the aforesaid PD-L1 polypeptide, and to host cells, methods, and uses related thereto.Type: ApplicationFiled: April 29, 2021Publication date: June 8, 2023Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V.Inventors: Mateusz PUTYRSKI, Andreas ERNST, Svenja WIECHMANN, Andreas VON KNETHEN, Michael John PARNHAM
-
Patent number: 11427630Abstract: An inhibitor of IL-38 is useful for treating and/or preventing cancer in a subject. A pharmaceutical composition can include an inhibitor of IL-38. A method for treating and/or preventing cancer is carried out by administering an inhibitor of IL-38 in a therapeutically effective amount. Another method is useful for identifying an inhibitor of IL-38.Type: GrantFiled: May 7, 2018Date of Patent: August 30, 2022Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.Inventors: Andreas Weigert, Javier Mora, Bernhard Brüne, Mateusz Putyrski, Michael John Parnham, Andreas Ernst
-
Publication number: 20200277349Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.Type: ApplicationFiled: March 2, 2020Publication date: September 3, 2020Inventors: Andreas WEIGERT, Javier MORA, Bernhard BRUNE, Christina DILLMANN, Michael John PARNHAM, Gerd GEISSLINGER
-
Publication number: 20200200775Abstract: Diagnostic methods are useful for diagnosing neuropathic pain in a subject, for predicting whether a subject is at risk of developing neuropathic pain, or for determining whether a neuropathic pain therapy is successful. Tools for carrying out the aforementioned methods, include diagnostic devices, and oxidized lipids, for example, an epoxylipid, for use in the aforementioned methods.Type: ApplicationFiled: April 26, 2017Publication date: June 25, 2020Inventors: Marco SISIGNANO, Gerd GEISSLINGER, Michael John PARNHAM
-
Publication number: 20200165334Abstract: An inhibitor of IL-38 is useful for treating and/or preventing cancer in a subject. A pharmaceutical composition can include an inhibitor of IL-38. A method for treating and/or preventing cancer is carried out by administering an inhibitor of IL-38 in a therapeutically effective amount. Another method is useful for identifying an inhibitor of IL-38.Type: ApplicationFiled: May 7, 2018Publication date: May 28, 2020Inventors: Andreas WEIGERT, Javier MORA, Bernhard BRÜNE, Mateusz PUTYRSKI, Michael John PARNHAM, Andreas ERNST
-
Patent number: 10618946Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.Type: GrantFiled: July 14, 2015Date of Patent: April 14, 2020Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.Inventors: Andreas Weigert, Javier Mora, Bernhard Brune, Christina Dillmann, Michael John Parnham, Gerd Geisslinger
-
Publication number: 20200101055Abstract: The present invention pertains to novel treatments of neuropathic pain; in particular chemotherapy induced peripheral neuropathic pain (CIPNP). The invention provides antagonists cytochrome P450 epoxygenases (CYP), and more specifically antagonists of CYP2J2, as therapeutics for use in the treatment of neuropathic pain such as CIPNP. CYP2J2 antagonists were identified to alleviate CIPNP in-vivo, and therefore are provided additionally in combination with chemotherapeutics for the treatment of diseases such as cancer or other proliferative disorders. The CYP2J2 antagonists reduce chemotherapeutic induced pain and therefore allow for a higher dosing of the chemotherapeutic during cancer treatment. In addition the invention relates to the use of CYP2J2 agonists, or metabolites of CYP2J2, for sensitizing TRPV1.Type: ApplicationFiled: October 7, 2019Publication date: April 2, 2020Inventors: Marco SISIGNANO, Christian BRENNEIS, Klaus SCHOLICH, Gerd GEISSLINGER, Sebastian ZINN, Michael John PARNHAM
-
Patent number: 10093628Abstract: The present invention pertains to a new compound E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl) benzyl)oxy)-benzylidene) hexanoic acid (MTTB), and its derivatives. The compounds of the invention are useful as selective peroxisome proliferator-activated receptor gamma (PPAR?) antagonists and are indicated for the use in the treatment of immune related diseases such as systemic inflammation, sepsis and septic shock.Type: GrantFiled: July 14, 2015Date of Patent: October 9, 2018Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖDERUNG DER ANGEWANDTEN FORSCHUNG E.V.Inventors: Tilo Knape, Andreas Von Knethen, Michael John Parnham, Manfred Schubert-Zsilavecz, Mario Wurglics, Daniel Flesch
-
Publication number: 20170266169Abstract: The present invention pertains to novel treatments of neuropathic pain; in particular chemotherapy induced peripheral neuropathic pain (CIPNP). The invention provides antagonists cytochrome P450 epoxygenases (CYP), and more specifically antagonists of CYP2J2, as therapeutics for use in the treatment of neuropathic pain such as CIPNP. CYP2J2 antagonists were identified to alleviate CIPNP in-vivo, and therefore are provided additionally in combination with chemotherapeutics for the treatment of diseases such as cancer or other proliferative disorders. The CYP2J2 antagonists reduce chemotherapeutic induced pain and therefore allow for a higher dosing of the chemotherapeutic during cancer treatment. In addition the invention relates to the use of CYP2J2 agonists, or metabolites of CYP2J2, for sensitizing TRPV1.Type: ApplicationFiled: August 14, 2015Publication date: September 21, 2017Inventors: Marco SISIGNANO, Christian BRENNEIS, Klaus SCHOLICH, Gerd GEISSLINGER, Sebastian ZINN, Michael John PARNHAM
-
Publication number: 20170218039Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.Type: ApplicationFiled: July 14, 2015Publication date: August 3, 2017Inventors: Andreas WEIGERT, Javier MORA, Bernhard BRÜNE, Christina DILLMANN, Michael John PARNHAM, Gerd GEISSLINGER
-
Publication number: 20170210711Abstract: The present invention pertains to a new compound E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl) benzyl)oxy)-benzylidene) hexanoic acid (MTTB), and its derivatives. The compounds of the invention are useful as selective peroxisome proliferator-activated receptor gamma (PPAR?) antagonists and are indicated for the use in the treatment of immune related diseases such as systemic inflammation, sepsis and septic shock.Type: ApplicationFiled: July 14, 2015Publication date: July 27, 2017Inventors: Tilo KNAPE, Andreas VON KNETHEN, Michael John PARNHAM, Manfred SCHUBERT-ZSILAVECZ, Mario WURGLICS, Daniel FLESCH